Recovery of Platelet Function After Discontinuation of Prasugrel or Clopidogrel Maintenance Dosing in Aspirin-Treated Patients With Stable Coronary Disease

Matthew J. Price(Scripps Clinic), Dominick J. Angiolillo(University of Florida), Darell Heiselman(Eli Lilly (United States)), Brian Baker, Wei Li(Harbin Medical University), Kenneth J. Winters(Eli Lilly (United States)), James Walder(University of North Carolina at Chapel Hill), Joseph A. Jakubowski(Indiana Biosciences Research Institute), Douglas Logan(Medpace (United States))
Journal of the American College of Cardiology
June 1, 2012
10.1016/j.jacc.2012.02.042
Cited by 116

Related Papers

Prasugrel Compared With High Loading- and Maintenance-Dose Clopidogrel in Patients With Planned Percutaneous Coronary Intervention
|Circulation|2007|882
Effect of Platelet Inhibition with Cangrelor during PCI on Ischemic Events
|New England Journal of Medicine|2013|825
Greater Clinical Benefit of More Intensive Oral Antiplatelet Therapy With Prasugrel in Patients With Diabetes Mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in Myocardial Infarction 38
|Circulation|2008|757
Pretreatment with Prasugrel in Non–ST-Segment Elevation Acute Coronary Syndromes
|New England Journal of Medicine|2013|651
Platelet Inhibition with Cangrelor in Patients Undergoing PCI
|New England Journal of Medicine|2009|618